Literature DB >> 9925650

Molecular defects underlying Wolman disease appear to be more heterogeneous than those resulting in cholesteryl ester storage disease.

P Lohse1, S Maas, A C Sewell, D Seidel.   

Abstract

Human lysosomal acid lipase/cholesteryl ester hydrolase (hLAL) is essential for the intralysosomal metabolism of cholesteryl esters and triglycerides taken up by receptor-mediated endocytosis of lipoprotein particles. The key role of the enzyme in intracellular lipid homeostasis is illustrated by two lysosomal storage diseases inherited as autosomal recessive traits. Wolman disease, associated with deficient hLAL activity, leads to massive intracellular substrate accumulation and is always fatal in early infancy. Cholesteryl ester storage disease (CESD), in contrast, is characterized by very low levels of enzymic activity sufficient to allow survival of the affected patients into adulthood. In order to elucidate the underlying molecular defects in Wolman disease, we have characterized the hLAL gene in two female Wolman patients of German and Turkish origin by SSCP and DNA sequence analysis. Our results demonstrate that the German proband was compound heterozygous for an 8-bp deletion in exon 3 and a 2-bp deletion in exon 4 of the hLAL gene. These frameshift mutations lead to protein truncation at amino acid positions 24 and 116 and to complete loss of hydrolytic activity. The Turkish proband, in contrast, was homozygous for a G(1064)-->T substitution in exon 10 of the hLAL gene which converts the completely conserved glycine (GGG) residue at position 321 of the mature enzyme to tryptophan (TGG). In vitro expression of the hLAL(Gly(321)-->Trp) cDNA construct revealed that the amino acid replacement results in a more than 99% reduction of neutral lipid hydrolysis. The mutations provide new insights into the molecular basis of Wolman disease which is apparently more heterogeneous at the genetic level than cholesteryl ester storage disease.-Lohse, P., S. Maas, P. Lohse, A. C. Sewell, O. P. van Diggelen, and D. Seidel. Molecular defects underlying Wolman disease appear to be more heterogeneous than those resulting in cholesteryl ester storage disease.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9925650

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  7 in total

1.  Severe chronic diarrhea and weight loss in cholesteryl ester storage disease: a case report.

Authors:  Uta Drebber; Matthias Andersen; Hans U Kasper; Peter Lohse; Manfred Stolte; Hans P Dienes
Journal:  World J Gastroenterol       Date:  2005-04-21       Impact factor: 5.742

Review 2.  Cholesterol ester storage disease (CESD) diagnosed in an asymptomatic adult.

Authors:  Hemant Chatrath; Steven Keilin; Bashar M Attar
Journal:  Dig Dis Sci       Date:  2008-05-14       Impact factor: 3.199

3.  Intragenic deletion as a novel type of mutation in Wolman disease.

Authors:  Teresa M Lee; Mariko Welsh; Sonia Benhamed; Wendy K Chung
Journal:  Mol Genet Metab       Date:  2011-09-14       Impact factor: 4.797

Review 4.  Early steps in steroidogenesis: intracellular cholesterol trafficking.

Authors:  Walter L Miller; Himangshu S Bose
Journal:  J Lipid Res       Date:  2011-10-05       Impact factor: 5.922

Review 5.  Gene therapy for dyslipidemia: clinical prospects.

Authors:  D J Rader; U J Tietge
Journal:  Curr Atheroscler Rep       Date:  1999-07       Impact factor: 5.113

6.  Gene therapy for lipid disorders.

Authors:  Daniel J Rader
Journal:  Curr Control Trials Cardiovasc Med       Date:  2000

Review 7.  Targeting Wolman Disease and Cholesteryl Ester Storage Disease: Disease Pathogenesis and Therapeutic Development.

Authors:  Francis Aguisanda; Natasha Thorne; Wei Zheng
Journal:  Curr Chem Genom Transl Med       Date:  2017-01-30
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.